Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts
http://www.reportlinker.com/p0865302/Non-Insulin-Diabetes-Management-Products-Players-Markets-and-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
The diabetes market is changing. The convergence of environmental factors, lifestyle factors and increased patient longevity are driving double-digit growth projections for the incidence of non-insulin dependent (Type 2) diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes and is increasingly being diagnosed in children and adolescents. There are eight drug classes, analyzed in this report, with proven efficacy for aiding in glycemic control in this patient population. Because of the size and business potential of this market, pipeline activity is high. In addition to derivative products and products that combine approved APIs in a single dosage form, drugs based on newer chemistries and mechanisms that include amylin analogs and GLP-1 drugs have been introduced. Globally, revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011 and 2016. Safety issues associated with post-launch-reported events will continue to be a major concern for market participants.
Highlights· Provides assessments of diabetes managemnet markets for non-insulin drugsl and examines key market and commercialization factors
· Evaluates the impact of economic, technology, and regulatory factors on diabetes management markets
· Provides market data and forecasts to 2016
· Profiles market sector participants, their product development activities and business strategies
Summary of ContentsDiabetes Management Market Dynamics
The Economics of Diabetes
Therapeutic Options and Patient Outcomes
Evolving Healthcare Initiatives
Demand Drivers
Competitive Landscape
Risk Factors
Non-Insulin Diabetes Management – Product Development Factors
Formulation and Administration
Oral Form Factors
Injectable Formulations
Dosing Frequency
Injectable Device Strategies
Clinical Trial Factors
Combination Therapeutics
Non-Insulin Drug Therapeutics – Classes, Mechanisms and Prescribing Factors
Alpha-glucosidase Inhibitors
Amylin Analogs
Di-peptidyl peptidase IV
Glitazones (Thiazolidinediones)
Glucagon-Like Peptide-1 (GLP-1)
Metformin
Meglitinides
Sulfonylureas
Non-Insulin Drug Therapeutics – Commercial Product Assessments
Branded Drugs
Alpha-glucosidase Inhibitors
Glyset (Miglitol)
Precose (Acarbose)
Amylin Analogs
Symlin (pramlintide acetate)
Dipeptidyl peptidase IV
Januvia (Sitagliptin)
Onglyza (BMS)
Tradjenta (Linagliptin)
Glitazones (Thiazolidinediones)
Pioglitazones
Rosiglitazones
Glucagon-Like Peptide-1 (GLP-1)
Byetta (Amylin)
Bydureon (Amylin)
Victoza (NovoNordisk)
Meglitinides
Starlix (Nateglinide)
Prandin (Repaglinide)
Sulfonylureas
Glipizide
Glimepirides
Other Therapeutic Classes
Dopamine Receptor Agonists
Combination Drug Products
Actoplus Met (Takeda)
Avandamet (GloxoSmithKline)
Avandaryl (GlaxoSmithKline)
Duetact (Takeda)
Glucovance (BMS)
Janumet (Merck)
Jentadueto (Boehringer Ingelheim)
Kombiglyze XR (BMS)
Metaglip (BMS)
Prandimet (NovoNordisk)
Commercialized Drugs Not Approved by the FDA
Alpha-glucosidase Inhibitors
Basen (Voglibose)
Alogliptin
Galvus (Vildagliptin)
Nesina
Generic Non-Insulin Diabetes Management Drugs
Pipeline Candidates - Analysis and Prospects
Dipeptidyl peptidase IV
Dutogliptin (Phenomix)
Gemigliptin (LG Life Sciences)
Glucagon-Like Peptide-1 (GLP-1)
Lyxumia (Lixisenatide)
Syncria (GlaxoSmithKline)
Peroxisome Proliferator-activated Receptor agonist (PPAR)
Aleglitazar
SGLT2 Inhibitors
Dapagliflozin
Canagliflozin
Non-Insulin Diabetes Management - Market Segment Analysis & Forecasts
Analysis and Forecasts by Drug Class
Analysis and Forecasts by Region
Market Factors
Regulatory Factors
North America
European Union
Japan
Demographic Factors
Safety and Reporting
Patient Compliance Factors
Sector Participant Company Profiles
To order this report:Drug and Medication Industry: Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article